&nbsp;

Mar 2024

Drug

letrozole

Other Name(s): Femara®

Quick Link(s):

May 2022

Drug

lapatinib

Other Name(s): Tykerb®

Quick Link(s):

Dec 2022

Drug

lomustine

Other Name(s): CeeNU®

Quick Link(s):

Aug 2024

Drug

lanreotide

Other Name(s): Somatuline® Autogel®

Quick Link(s):

Jun 2024

Regimen

LENA

Cancer Type:

Hematologic,

Myelodysplastic Syndrome (MDS)

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the treatment of patients with anemia due to myelodysplastic syndrome (MDS), according to clinical criteria

Drugs Used:

lenalidomide

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LOMU

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

Drugs Used:

lomustine

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

LENA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria

Drugs Used:

lenalidomide

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LANR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

lanreotide

Drugs Used:

lanreotide

Quick Link(s):

Regimen Monograph

May 2024

Regimen

LENA

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Palliative

Drugs Used:

lenalidomide (Unfunded)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LENA(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Drugs Used:

lenalidomide (Unfunded)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LOMU+BEVA

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma

Drugs Used:

lomustine,

bevacizumab